Device Trial Radar · NCT05305534
QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study
Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,142
Actual
Start
Dec 1, 2023
Primary completion
Apr 10, 2025
Study completion Aug 25, 2025
Sponsor
- Lead sponsor
- QIAGEN Gaithersburg, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 31, 2022
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study for performance evaluation of the QIAstat-Dx® BCID Plus AMR GPF-Panel and the QIAstat Dx® BCID Plus AMR GN-Panel in comparison with other chosen comparator methods
Conditions
- Blood Disease
Interventions
QIAstat-Dx® BCID GN and GPF Plus AMR PanelsDevice
The performance of QIAstat-Dx® BCID GN and GPF Plus AMR Panels will be evaluated in comparison with another validated comparator method, using residual specimens of positive blood culture. Pure colonies derived from the residual positive blood culture specimens will also be tested
Primary outcomes
What the sponsor says the trial is designed to measure.
- PPATime frame: 6 moths
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
QIAGEN
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.